Neuropathic Pain (Neuralgia) is an indication for drug development with over 430 pipeline drugs currently active. According to GlobalData, preregistered drugs for Neuropathic Pain (Neuralgia) have a 83.33% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Neuropathic Pain (Neuralgia) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Neuropathic Pain (Neuralgia) overview
Neuropathic pain, also known as neuralgia, is a complex and chronic condition characterized by pain that arises from damage or dysfunction of the nervous system. Unlike nociceptive pain, which arises from tissue damage, neuropathic pain results from abnormal signaling within the nervous system itself. This type of pain can manifest in various ways, including shooting or burning sensations, tingling, numbness, or hypersensitivity to touch. It is often chronic and debilitating, significantly impacting the quality of life for those affected. Neuropathic pain can have numerous causes, including diabetes, trauma, infections etc.
For a complete picture of PTSR and LoA scores for drugs in Neuropathic Pain (Neuralgia), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
